157 related articles for article (PubMed ID: 25756405)
1. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary.
Taniguchi F; Itamochi H; Harada T; Terakawa N
Int J Gynecol Cancer; 2013 Jun; 23(5):791-6. PubMed ID: 23640291
[TBL] [Abstract][Full Text] [Related]
3. Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.
Czaplinska D; Mieczkowski K; Supernat A; Skladanowski AC; Kordek R; Biernat W; Zaczek AJ; Romanska HM; Sadej R
Tumour Biol; 2016 Oct; 37(10):13721-13731. PubMed ID: 27476168
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
[TBL] [Abstract][Full Text] [Related]
7. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
9. Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.
Itamochi H; Oumi N; Oishi T; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Clin Oncol; 2015 Oct; 20(5):967-73. PubMed ID: 25744580
[TBL] [Abstract][Full Text] [Related]
10. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
12. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3.
Min KW; Park MH; Hong SR; Lee H; Kwon SY; Hong SH; Joo HJ; Park IA; An HJ; Suh KS; Oh HK; Yoo CW; Kim MJ; Chang HK; Jun SY; Yoon HK; Chang ED; Kim DW; Kim I;
Int J Gynecol Pathol; 2013 Jan; 32(1):3-14. PubMed ID: 23202783
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
[TBL] [Abstract][Full Text] [Related]
14. KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear‑cell carcinoma cells.
Kawai Y; Shibata K; Sakata J; Suzuki S; Utsumi F; Niimi K; Sekiya R; Senga T; Kikkawa F; Kajiyama H
Oncol Rep; 2018 Jul; 40(1):195-205. PubMed ID: 29749467
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
Hirata Y; Murai N; Yanaihara N; Saito M; Saito M; Urashima M; Murakami Y; Matsufuji S; Okamoto A
BMC Cancer; 2014 Nov; 14():799. PubMed ID: 25366985
[TBL] [Abstract][Full Text] [Related]
16. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
Hazama Y; Moriya T; Sugihara M; Sano R; Shiota M; Nakamura T; Shimoya K
Int J Gynecol Pathol; 2018 Nov; 37(6):516-524. PubMed ID: 29019869
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Abe A; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
Hum Pathol; 2013 Feb; 44(2):199-207. PubMed ID: 22955107
[TBL] [Abstract][Full Text] [Related]
18. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.
Zhu DY; Guo QS; Li YL; Cui B; Guo J; Liu JX; Li P
World J Gastroenterol; 2014 Dec; 20(48):18306-15. PubMed ID: 25561797
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pure and mixed-type clear cell carcinoma of the ovary: a clinicopathological analysis of 341 Chinese patients.
Ye S; You Y; Yang J; Cao D; Bai H; Huang H; Wu M; Chen J; Lang J; Shen K
Int J Gynecol Cancer; 2014 Nov; 24(9):1590-6. PubMed ID: 25254564
[TBL] [Abstract][Full Text] [Related]
20. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
Takaya A; Peng WX; Ishino K; Kudo M; Yamamoto T; Wada R; Takeshita T; Naito Z
Int J Oncol; 2015 Apr; 46(4):1573-81. PubMed ID: 25633807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
